Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.41 |
| ▸ | HTR5A | P47898 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HK1 | P19367 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL517635 | 1.00 | ALOX15 (0.52) | ALOX15HSD17B10GAAMAPTPARP1 | |
| SCHEMBL29749158 | 1.00 | ALOX15 (0.52) | ALOX15HSD17B10GAAMAPTPARP1 | |
| SCHEMBL17667590 | 0.80 | GAA (0.39) | ALOX15HSD17B10GAAMAPTPARP1 | |
| SCHEMBL17667588 | 0.80 | GAA (0.39) | ALOX15HSD17B10GAAMAPTPARP1 | |
| SCHEMBL17667600 | 0.80 | GAA (0.39) | ALOX15HSD17B10GAAMAPTPARP1 | |
| SCHEMBL4046186 | 0.80 | TRPA1 (0.40) | ALOX15HSD17B10GAAMAPTPARP1 | |
| SCHEMBL17667601 | 0.80 | GAA (0.39) | ALOX15HSD17B10GAAMAPTPARP1 | |
| SCHEMBL4046182 | 0.80 | TRPA1 (0.40) | ALOX15HSD17B10GAAMAPTPARP1 | |
| SCHEMBL20777448 | 0.79 | GAA (0.46) | ALOX15HSD17B10GAAMAPTPARP1 | |
| SCHEMBL6137103 | 0.77 | MAPT (0.48) | ALOX15HSD17B10GAAMAPTPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11242359-B2 | Biocompatible modular tetrazine platform | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-02-08 | — | — | US | claimed |
| US-20200354381-A1 | BIOCOMPATIBLE MODULAR TETRAZINE PLATFORM | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-11-12 | — | — | US | claimed |
| EP-3609885-A1 | BIOCOMPATIBLE MODULAR TETRAZINE PLATFORM | Centre National De La Recherche Scientifique (FR) | 2020-02-19 | — | — | EP | claimed |
| WO-2018172543-A1 | BIOCOMPATIBLE MODULAR TETRAZINE PLATFORM | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-09-27 | — | — | WO | claimed |
| EP-4393937-A1 | STEROID COMPOUND AND CONJUGATE THEREOF | Duality Biologics (Suzhou) Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| EP-3903826-B1 | BIOMOLECULE CONJUGATES | CELGENE CORP (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-4065978-B1 | NOVEL LINKER COMPOUNDS | CAMBRIDGE ENTPR LTD (GB) | 2023-12-13 | — | — | EP | disclosed |
| EP-4289483-A2 | BIOMOLECULE CONJUGATES | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-4268857-A1 | NOVEL MULTILAYER POLYMER-COATED CROSSLINKED ALGINATE GEL FIBER | Mochida Pharmaceutical Co., Ltd. (JP) | 2023-11-01 | — | — | EP | disclosed |
| WO-2023180489-A1 | ANTIBODY-CONJUGATES FOR TARGETING OF TUMOURS EXPRESSING CARCINOEMBYRONIC ANTIGEN | SYNAFFIX B.V. (NL) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023180485-A1 | ANTIBODY-CONJUGATES FOR TARGETING OF TUMOURS EXPRESSING TROP-2 | SYNAFFIX B.V. (NL) | 2023-09-28 | — | — | WO | disclosed |
| US-20230286920-A1 | CYCLOOCTYNES FOR CLICK CHEMISTRY | MASSACHUSETTS INST TECHNOLOGY (US) | 2023-09-14 | — | — | US | disclosed |
| US-8039474-B2 | 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-10-18 | — | — | US | disclosed |
| US-7897788-B2 | Indol-1-yl-acetic acid derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-03-01 | — | — | US | disclosed |
| EP-1740171-B1 | INDOL-1-YL-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-06-09 | — | — | EP | disclosed |
| US-7417040-B2 | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-20070208004-A1 | Indol-1-yl-acetic acid derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-09-06 | — | — | US | disclosed |
| EP-1021190-A4 | NOVEL AMIDE DERIVATIVES | KAKEN PHARMA CO LTD (JP) | 2004-08-18 | — | — | EP | disclosed |
| EP-1021190-A1 | NOVEL AMIDE DERIVATIVES | Kaken Pharmaceutical Co., Ltd. (JP) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999009991-A1 | NOVEL AMIDE DERIVATIVES | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354381-A1 | BIOCOMPATIBLE MODULAR TETRAZINE PLATFORM | DYRK4, TALDO1, DYRK3 | ALOX15 1212/4885HSD17B10 1833/4885GAA 1807/4885 |
| US-20230286920-A1 | CYCLOOCTYNES FOR CLICK CHEMISTRY | CBR3, CYCS, APOBEC3C | ALOX15 200/4885HSD17B10 1158/4885GAA 4729/4885 |
| US-20070208004-A1 | Indol-1-yl-acetic acid derivatives | IDO1, IDO2, AANAT | ALOX15 1439/4885HSD17B10 620/4885GAA 239/4885 |
| US-11242359-B2 | Biocompatible modular tetrazine platform | DYRK4, TALDO1, DYRK3 | ALOX15 1212/4885HSD17B10 1833/4885GAA 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.